A randomised, phase II study to evaluate the efficacy and safety of cetuximab-based treatment in patients with chemotherapy-resistant refractory metastatic colorectal cancer with KRAS G13D mutation.
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 10 Jul 2017 New trial record